News
AstraZeneca begins DTC home delivery of self-administered FluMist vaccine
FluMist has been approved since 2003, but—until last year—only for administration by a healthcare practitioner. The new nod allows adults up to 49 years old to use the nasal spray themselves, while parents and caregivers can give it to children aged 2 to 17.
The treatment is one for those suffering with lung cancer who never smoked, a group of patients who account for up to 25% of those who develop the disease due to an oncogenic driver mutation. Tagrisso ...
Stocktwits on MSN10h
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca
FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...
AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...
Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...
While the numbers may seem high, they are still far below the pay of top executives in the United States, the study has found ...
He said about Britain that the firm needed “to see that there is access and a reason to invest.” This is partly a negotiating tactic to get a better deal from the British government, including on what ...
AstraZeneca PLC closed 13.46% below its 52-week high of £133.88, which the company reached on September 3rd.
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...
AstraZeneca has launched FluMist Home, a nasal spray flu vaccine with at-home delivery service. For those who have a needle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback